Business Context and Reporting Period
This Form 8-K Current Report for Dare Bioscience, Inc. covers events occurring on November 30, 2018, and December 5, 2018. The filing details the entry into material definitive agreements regarding intellectual property licensing and a notification from Nasdaq regarding the company's stock price compliance.
Key Financial Metrics and Agreements
The filing does not provide standard financial statements (revenue, profit, cash flow, or debt levels) as it is a current report on specific events. However, it outlines significant financial obligations and commitments arising from new agreements:
- Upfront Payments: Dare paid $25,000 to MilanaPharm and $250,000 to Hammock Pharmaceuticals upon execution of the agreements.
- Deferred Fees: Dare must pay $200,000 to MilanaPharm and $250,000 to Hammock within 15 days of the earlier of December 5, 2019, or the closing of an equity financing raising at least $10.0 million. These may be paid in cash or stock.
- Milestone Payments: Potential future development milestones total up to $300,000 to MilanaPharm and up to $1.1 million to Hammock. Commercial milestones include up to $500,000 per product category for MilanaPharm and a $1.0 million payment upon $50 million in cumulative sales.
- Royalties: Dare will pay high single-digit to low double-digit royalties on annual worldwide net sales to MilanaPharm.
Material Changes and Events
Acquisition of License (Item 1.01): Dare acquired an exclusive, royalty-bearing, worldwide license for the TRI-726 hydrogel drug delivery platform for intravaginal and urological applications. This was achieved through an Assignment Agreement with Hammock Pharmaceuticals and a License Amendment with TriLogic Pharma and MilanaPharm.
Nasdaq Listing Deficiency (Item 3.01): On November 30, 2018, Dare received notice from Nasdaq that its common stock closing bid price had been below the $1.00 minimum requirement for 30 consecutive business days. The company has been granted an initial 180-day compliance period (until May 29, 2019) to regain compliance.
Outlook, Risks, and Management Commentary
Compliance Risk: There is no assurance that Dare will regain compliance with the Nasdaq Minimum Bid Price Requirement. Failure to do so could result in delisting, though the company may be eligible for an additional 180-day period if it meets other listing standards and effects a reverse stock split if necessary.
Operational Obligations: Dare is required to use commercially reasonable efforts to develop and commercialize at least one licensed product in the United States and at least one in a specified European country or Canada.
Confidentiality: Dare expects to seek confidential treatment for certain terms of the agreements when filed in the annual Form 10-K.
Investor Verification Checklist
- Verify the current closing bid price of Dare Bioscience stock to assess the risk of delisting before the May 29, 2019, compliance deadline.
- Monitor upcoming equity financing announcements to determine if the $10.0 million threshold is met, which would trigger the $450,000 in deferred fees.
- Review the upcoming Form 10-K for the full text of the MilanaPharm License Agreement and Assignment Agreement to understand specific royalty reduction clauses and termination rights.
- Assess the company's cash position to ensure it can fund the upfront payments and future development milestones without immediate dilution.